Skip to main content
SpringerLink
Log in

Combination of PARP Inhibitors with Clinical Radiotherapy

  • Chapter
  • First Online:
PARP Inhibitors for Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D,volume 83))

Abstract

Radiosensitisation of solid tumours by manipulation of the DNA damage response offers an opportunity to increase the effectiveness of radiotherapy in terms of enhanced local tumour control, better alleviation of symptoms and improved cure rates. PARP inhibitors are the best characterised DNA damage response inhibitors and possess many qualities that predict clinical utility as radiosensitisers. Pre-clinical data indicate that PARP inhibitors will provide tumour specific radiosensitisation and may be effective radiosensitisers of hypoxic tumour cells and cancer stem cells. They have minimal systemic toxicity as single agents and if combined with modern radiotherapy technology are likely to have acceptable ‘in-field’ toxicity. As such, they represent ideal candidate radiosensitisers for development in clinical trials. Significant challenges and opportunities exist in designing appropriate clinical trials that will assess toxicity and benefit from these agents in a rigorous manner. This chapter reviews the clinical rationale for the use of PARP inhibitors as radiosensitisers and summarises their current clinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104(6):1129–1137. doi:10.1002/cncr.21324

    Article  PubMed  Google Scholar 

  2. Schaue D, McBride WH (2005) Counteracting tumor radioresistance by targeting DNA repair. Mol Cancer Ther 4(10):1548–1550. doi:10.1158/1535-7163.MCT-05-CO1

    Article  CAS  PubMed  Google Scholar 

  3. Fleck O, Nielsen O (2004) DNA repair. J Cell Sci 117(Pt 4):515–517. doi:10.1242/jcs.00952

    Article  CAS  PubMed  Google Scholar 

  4. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461(7267):1071–1078. doi:10.1038/nature08467

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Thompson LH (2012) Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 751(2):158–246. doi:10.1016/j.mrrev.2012.06.002

    Article  CAS  PubMed  Google Scholar 

  6. Hiom K (2010) Coping with DNA double strand breaks. DNA Repair 9(12):1256–1263. doi:10.1016/j.dnarep.2010.09.018

    Article  CAS  PubMed  Google Scholar 

  7. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J (2010) Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 29(36):5095–5102. doi:10.1038/onc.2010.249

    Article  CAS  PubMed  Google Scholar 

  8. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864–870. doi:10.1038/nature03482

    Article  CAS  PubMed  Google Scholar 

  9. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell A, Ekblad T, Oncu D, Kull B, Robertson GM, Pellicciari R, Schuler H, Weigelt J (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nature Biotechnol 30(3):283–288. doi:10.1038/nbt.2121

    Article  CAS  Google Scholar 

  10. Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205(2):155–160. doi:10.1016/j.canlet.2003.10.029

    Article  CAS  PubMed  Google Scholar 

  11. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (an official journal of the American Association for Cancer Research) 13(10):3033–3042. doi:10.1158/1078-0432.CCR-06-2872

    Article  CAS  PubMed  Google Scholar 

  12. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (an official journal of the American association for cancer research) 13(9):2728–2737. doi:10.1158/1078-0432.CCR-06-3039

    Article  CAS  PubMed  Google Scholar 

  13. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K (2009) In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res (an official journal of the American association for cancer research) 15(2):607–612. doi:10.1158/1078-0432.CCR-08-2079

    Article  CAS  PubMed  Google Scholar 

  14. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN (2009) Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8(2):407–414. doi:10.1158/1535-7163.MCT-08-0854

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, Xu W, Hoover RK, Lauter S, O'Malley B Jr, Lapidus RG, Li D (2010) Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head neck 32(3):381–391. doi:10.1002/hed.21195

    PubMed  Google Scholar 

  16. Noel G, Godon C, Fernet M, Giocanti N, Megnin-Chanet F, Favaudon V (2006) Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5(3):564–574. doi:10.1158/1535-7163.MCT-05-0418

    Article  CAS  PubMed  Google Scholar 

  17. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9(6):1775–1787. doi:10.1158/1535-7163.MCT-09-1027

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, Bosco P, Castiglione R, Salemi M (2012) PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem: EJH 56(1):e9. doi:10.4081/ejh.2012.e9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96(1):56–67. doi:10.1093/Jnci/Djh005

    Article  CAS  PubMed  Google Scholar 

  20. Godon C, Cordelieres FP, Biard D, Giocanti N, Megnin-Chanet F, Hall J, Favaudon V (2008) PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 36(13):4454–4464. doi:10.1093/nar/gkn403

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599. doi:10.1158/0008-5472.CAN-12-2753

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ (2011) The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 10(12):2320–2329. doi:10.1158/1535-7163.MCT-11-0356

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A (2008) Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med 22(1):113–118

    CAS  PubMed  Google Scholar 

  24. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG (2008) A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol (journal of the European society for therapeutic radiology and oncology) 88(2):258–268. doi:10.1016/j.radonc.2008.04.005

    Article  CAS  PubMed  Google Scholar 

  25. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111. doi:10.1038/35102167

    Article  CAS  PubMed  Google Scholar 

  26. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760. doi:10.1038/nature05236

    Article  CAS  PubMed  Google Scholar 

  27. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN (2013) Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. doi:10.1038/cdd.2013.136

    Google Scholar 

  28. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. doi:10.1056/NEJMoa0900212

    Article  CAS  PubMed  Google Scholar 

  29. Hobson B, Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49(4):405–413

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Roesner JP, Vagts DA, Iber T, Eipel C, Vollmar B, Noldge-Schomburg GF (2006) Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats. Intensive Care Med 32(10):1649–1657. doi:10.1007/s00134-006-0335-y

    Article  CAS  PubMed  Google Scholar 

  31. Hamahata A, Enkhbaatar P, Lange M, Yamaki T, Sakurai H, Shimoda K, Nakazawa H, Traber LD, Traber DL (2012) Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model. Burns (journal of the international society for burn injuries) 38(8):1210–1215. doi:10.1016/j.burns.2012.08.021

    Article  PubMed  Google Scholar 

  32. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G (2006) Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J (official publication of the federation of American societies for experimental biology) 20(10):1709–1711. doi:10.1096/fj.06-5916fje

    Article  CAS  PubMed  Google Scholar 

  33. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 30(4):1493–1500. doi:10.1007/s10637-011-9682-9

    Article  CAS  PubMed  Google Scholar 

  34. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 6(3):945–956. doi:10.1158/1535-7163.MCT-06-0552

    Article  CAS  PubMed  Google Scholar 

  35. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ (2011) Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103(4):334–346. doi:10.1093/jnci/djq509

    Article  CAS  PubMed  Google Scholar 

  36. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (an official journal of the American association for cancer research) 14(23):7917–7923. doi:10.1158/1078-0432.CCR-08-1223

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H (2013) A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 71(5):1191–1199. doi:10.1007/s00280-013-2113-1

    Article  CAS  PubMed  Google Scholar 

  38. Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ (2014) Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. doi:10.1038/bjc.2014.91

    Google Scholar 

  39. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH (2012) A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (an official journal of the American association for cancer research) 18(6):1726–1734. doi:10.1158/1078-0432.CCR-11-2821

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cancer Sciences, University of Glasgow, Garscube Estate, G61 0BD, Glasgow, UK

    Ross Carruthers & Anthony J Chalmers

Authors
  1. Ross Carruthers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony J Chalmers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony J Chalmers .

Editor information

Editors and Affiliations

  1. Northern Institute for Cancer Research and Newcastle University Institute for Ageing Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom

    Nicola J. Curtin

  2. CRUK-MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom

    Ricky A. Sharma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Carruthers, R., Chalmers, A. (2015). Combination of PARP Inhibitors with Clinical Radiotherapy. In: Curtin, N., Sharma, R. (eds) PARP Inhibitors for Cancer Therapy. Cancer Drug Discovery and Development, vol 83. Humana Press, Cham. https://doi.org/10.1007/978-3-319-14151-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14151-0_23

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-14150-3

  • Online ISBN: 978-3-319-14151-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation